Nick Mordwinkin

Leading business development, corporate strategy, and business operations (including finance, investor/public relations, facilities, and IT).

Led the company’s efforts to conceive, structure and negotiate strategic partnership and business development arrangements that supplemented and enhanced Kezar’s growth and strategic mission. As a member of the executive team, worked collaboratively with other key leaders to develop and implement the company’s growth strategy, with full cycle responsibility for all business development and strategic planning activity. Oversaw corporate strategy, business development, alliance management and investor relations. Selected Transaction Experience: -Collaboration and License Agreement with Everest Medicines for Zetomipzomib in Greater China, South Korea and Southeast Asia (2023)

Led corporate development activities for all of Gilead’s inflammation/fibrosis franchise and supported the full range of deal making activities including search and evaluation, due diligence, negotiation, and transaction execution. Served as a key advisor for a diverse set of senior stakeholders across research, development, commercial and other functions. Also focused on research/platform technologies and data science opportunities. Selected Transaction Experience: -Curebase Series B Investment (2022) -NASH Clinical Collaboration with Novo Nordisk (2021) -Commercialization and Distribution of Jyseleca in Asia with Eisai (2021)

Led the corporate strategy team and long-range corporate strategic planning process, including valuation of current pipeline programs and business development opportunities, and assessment of enterprise-level opportunities. Responsible for competitive and market/business intelligence, conference coverage, benchmarking and analytical/deal support, driving operational effectiveness and other cross-functional and cross-program initiatives. Selected Transaction Experience: -Partnership with Option to Acquire GeneTx Biotherapeutics (2020) -Acquisition of Dimension Therapeutics (2017)

Specialized in strategic, business, and technical problems for those in the biotech, pharma, healthcare, and biosciences industries. By combining its leadership and teams’ expertise, experience, and extensive network, provided high quality consulting services to companies ranging from startups to global firms. Also provided training for PhD students and postdocs who were looking to advance their business skills.

Performed extensive and rigorous fundamental research, due diligence, and industry analysis of companies in the biotechnology space, including data sourcing and detailed financial modeling. Acquired in-depth industry expertise by preparing and producing written reports around earnings results, presentations, and recommendations to clients. Interacted with company management as well as answered inquiries and communicated with sales, trading, and institutional clients, and broadly supported the senior analyst and sector franchise.

Responsible for the growth of a full line of immunology-based products throughout the San Francisco Bay Area and Colorado. Used my in-depth knowledge and expert technical skills to gain buy-in and acquire new customers from biotechnology companies, academic research institutions, and pharmaceutical companies, while simultaneously augmenting existing customer relationships. Analyzed the market for new product opportunities and acted as a knowledgeable resource for customers who had questions or product-related issues.

Inpatient staff pharmacist responsible for order entry and verification, identifying drug interactions, drug dosing, pharmacokinetics, parenteral nutrition, and training in a 557-bed acute care hospital.

Outpatient staff pharmacist specializing in the treatment of HIV/AIDS and transplant patients.

My research focused on the biological mechanisms of adult stem cells and induced pluripotent stem cells, including disease modeling and drug screening using induced pluripotent stem cell-derived cardiomyocytes and endothelial cells derived from patients diagnosed with diabetic cardiomyopathy. Authored/co-authored 6 papers.

Dissertation: The peptide angiotensin-(1-7) as a novel treatment for complications induced by type 2 diabetes mellitus. Authored/co-authored 7 papers

My research focused on the clinical therapeutic drug monitoring of antiretrovirals in HIV-positive patients by developing novel assays using techniques including liquid chromatography-tandem mass spectrometry and pharmacokinetic modeling. Authored/co-authored 7 papers.

Trained in acute care pharmacy practice and teaching, while increasing my clinical skills through direct patient exposure. Received extensive clinical experience in primary, secondary, and tertiary care settings. Through various rotations, refined my clinical skills, developed expertise as a drug therapy specialist, and became proficient in running a de-centralized pharmacy operation. Developed my teaching skills in both a clinical setting as well as in the classroom. Also developed administrative, research, and analytical skills, in addition to improving my understanding of pharmacy practice in the hospital setting. Helped to establish an antimicrobial stewardship program at USC University Hosptial.

Dual admission program, dean's list student.